Agios Pharmaceuticals Inc (STU:8AP)
€ 42 2.6 (6.6%) Market Cap: 2.40 Bil Enterprise Value: 1.91 Bil PE Ratio: 0 PB Ratio: 3.45 GF Score: 41/100

Agios Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript

Feb 25, 2020 / 03:30PM GMT
Release Date Price: €42.55 (-4.12%)
Andrew Scott Berens
SVB Leerink LLC, Research Division - MD of Targeted Oncology & Senior Research Analyst

All right. Why don't we get started. I'm Andy Berens, Senior Biotech Analyst at SVB Leerink, and we're pleased to have Jackie Fouse, CEO of Agios with us.

Thank you for joining us, Jackie.

Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Happy to be here.

Andrew Scott Berens
SVB Leerink LLC, Research Division - MD of Targeted Oncology & Senior Research Analyst

Appreciate it. I know, obviously, it's a name that a lot of people know, but maybe there's some people in the room that don't know the story. What -- can we just get a brief overview of the company before we dive in?

Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Sure. Sounds good. So I'm going to stand up for this. I just have like 3 or 4 slides to walk people through. For those of you who are less familiar with our story, these are the forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot